Even “minor” infections can cause ME/CFS

Simmaron Research blog post, by Cort Johnson, 5 July 2017: Even “Minor” Infections Can Cause Chronic Fatigue Syndrome (ME/CFS)

Giardia hasn’t historically ranked high as a potential cause of chronic fatigue syndrome (ME/CFS). Some anecdotal reports suggest that a Giardia outbreak may have occurred prior to the Incline Village ME/CFS outbreak in the 1980’s. More recently, Corinne Blandino’s severe, decades long case of ME/CFS – which originated with an exposure to Giardia at work – demonstrated how devastating a case of Giardia triggered ME/CFS can be.

It wasn’t until city in Norway got exposed to Giardia in 2004, however, that Giardia, a protozoa, became one of the pathogens definitively linked with chronic fatigue syndrome (ME/CFS). Large studies (n=1254) examining the aftermath of the outbreak in a public water system in Bergen found that five years later, almost 50% of those originally infected still had symptoms of irritable bowel syndrome and/or chronic fatigue (post-infectious chronic fatigue).

“Other patients suffer a severe, long lasting illness, for which treatment is ineffectual, and even after the parasite has finally been eliminated, some sequelae persist, affecting quality of life and continuing to cause the patient discomfort or pain” (LJ Robertson et al, 2010)

Five percent suffered from fatigue severe enough for them to lose employment or be unable to continue their education. Interestingly, all had taken anti-parasitic drugs and all had apparently cleared the pathogen from their systems.  Five years later, 30% were deemed to have an ME/CFS-like illness and almost 40% had irritable bowel syndrome  (IBS).

The Giardia ‘Syndrome’ Strikes: Norwegian Studies Suggest ‘Minor Bugs’ May Commonly Trigger Chronic Fatigue Syndrome As Well

“Minor” Infection – Sometimes Serious Results
By all accounts Giardia shouldn’t be doing this. Giardia is not normally considered a serious infection. Most people have some diarrhea and pass the bug quickly – and if they don’t, antibiotics are usually (but not always) effective. Giardia, seemingly, produces the kind of “minor” infection that our medical system doesn’t spend much time on.

The Mayo Clinic reports that Giardia infection (giardiasis) is one of the most common causes of waterborne illness in the United States. The parasites are found in backcountry streams and lakes throughout the U.S., but can also be found in municipal water supplies, swimming pools, whirlpool spas and wells. Giardia infection can be transmitted through food and person-to-person contact.

Research studies are slowly revealing that the effects of even vanquished Giardia infections can be long lasting for some. The Mayo Clinic reports that intestinal problems such as lactose intolerance  may be present long after the parasites are gone. (Even though half a dozen studies have been published on the Bergen outbreak, Mayo fails to note that long term issues with fatigue and pain (or ME/CFS) may result).

The Bergen studies indicate, however, that this rather common infection worldwide can cause long term and even at times debilitating fatigue as well. The takeaway lesson from the Bergen studies is that one doesn’t need to have mono, Ross-River virus or Valley fever or any of several serious infections to get seriously afflicted. As Dr. Chia has been saying about enteroviruses for years, any minor infection has the potential to cause ME/CFS in the right person.

Read more about the research into Giardia and ME/CFS 

Posted in News | Tagged , , , , , , | Comments Off on Even “minor” infections can cause ME/CFS

In memory of Dr Bruce Carruthers

Phoenix rising blog post: In memory of Dr Bruce Carruthers

Sherri Todd, has informed us of the passing of Dr. Bruce Carruthers. Dr. Carruthers is one of the two doctors who did the original drafts of the Canadian Clinical Definitions from which the medical panels worked to make the final definitions which became know as “The Canadian Definitions”.

Read the tributes

Obituary in Vancouver Sun, 29 July 2017
 

Posted in News | Tagged | Comments Off on In memory of Dr Bruce Carruthers

WAMES challenges NICE’s reason not to update the CFS/ME guidelines

WAMES sent our response to the NICE consultation on Monday 24th July 2017.

NICE asked: Do you agree with the proposal not to update the guideline?

WAMES replied:

We believe the NICE Guidance CG53 on CFS/ME omits guidelines on key issues, includes guidance that is potentially harmful and is misleading to both patients and clinicians. It is in need of urgent revision.

The decision not to review the guidelines has been taken on the basis that evidence in other trials support the original PACE trial results. No consideration has been given to the flaws that are common to all these trials.

i) broad patient selection criteria, ignoring the possibility of subgroups requiring different management approaches and ignoring the wide range of severity experienced by patients, or the possible differences between children and adults or men and women – research has repeatedly been shown that different criteria identifies different groups of patients and reduces the usefulness of research results e.g. Baraniuk,  Johnston  Nacul & Jason;

ii)    measuring only subjective outcomes;

iii)  the lack of double-blind, randomised, placebo-controlled trials, especially as some trials have actively sought to influence the results by promoting their approach as ‘the most effective therapies’;

iv)   assumptions about the nature of the illness, the factors that sustain it and the suitability of exercise therapy which are contradicted by scientific research into the illness.

We go on to challenge the decision to overlook the failings of the PACE trial and to call for stricter assessment of it and similar trials, by the Cochrane review panel. They should also take into account patient experience, and growing research evidence into the nature of the illness, the effect of exercise on the body and the way the post exertional response affects multiple symptoms.

Topics we believe are missing from the guidelines include:

  • help for healthcare and social care professionals to give ongoing care and management advice to patients who do not improve, who remain ill over a long period and who are severely affected
  • the difference between CBT aimed at changing negative illness beliefs and CBT designed to help people adapt and cope better with the limitations of the illness
  • Pharmacological interventions e.g. the use of amitriptyline for pain

We fear that a failure to update the Guideline will simply drive a bigger wedge between the medical and the patient communities, who do not find it a valuable or believable resource.

Read our full response

Read more about the consultation and the NICE proposal

Posted in News | Tagged , , , , , , , | Comments Off on WAMES challenges NICE’s reason not to update the CFS/ME guidelines

Another ‘False Start’ in ME/CFS Clinical Trials: The GETSET Study

Another ‘False Start’ in ME/CFS Clinical Trials: The GETSET Study, by Todd E. Davenport, PT, DPT, MPH, OCS

I am a physical therapist, and movement is my medicine. Some people might need more movement, in the form of an exercise program, while some people might need less movement, in the form of a pacing program.

I rely on scientific studies to help me decide who might benefit from which kind of treatment. Science helps me assign probabilities to outcomes, which I can then use to work with my patients collaboratively to establish the best possible treatment program to help them meet their goals. Reliable data from valid scientific studies can help me be more confident as a clinician that the decisions I make together with my patients actually will help them.

After starting my research career conducting clinical studies related to other fatiguing health conditions, I’ve now worked in the field of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) for over 10 years.

During that time, I’ve been fortunate to work with a caring and dedicated group of scientists and advocates. To say that the body of intervention studies in ME/CFS has involved disappointingly (and sometimes breathtakingly!) poor science is an understatement. The trend of poorly designed intervention studies, most recently headlined by the PACE trial, has just led to reinforcement of erroneous perceptions about ME/CFS without providing the tools necessary for clinicians like me to help ameliorate the devastating impact of ME/CFS on real peoples’ lives. So, it was with great interest that I read the GETSET study, which was recently published in the Lancet.

All the things that made me uneasy as a physical therapist about the PACE trial are back, now in the form of a study involving a slick self-help guide. It’s the same confirmation bias of telling folks to move in the context of a graded exercise program, and then having them parrot back the study hypothesis on standardized questionnaires. It’s the same absence of objective activity measures that result in the same self-fulfilling prophecy of telling people to move more, and then declaring victory when some of them are actually able to do it. It’s the same disregard for foundational scientific evidence of aerobic system compromise, immune activation, and other forms of organic pathophysiology in favor of a behavioral approach to ‘tell the tired people to move more.’

Read more

Todd Davenport is Associate Professor and Program Director: Department of Physical Therapy, University of the Pacific, Stockton, CA Clinical and Research Consultant: Workwell Foundation, Ripon, CA

Posted in News | Tagged , , , , | Comments Off on Another ‘False Start’ in ME/CFS Clinical Trials: The GETSET Study

Further commentary on the PACE trial: Biased methods & unreliable outcomes

Article abstract:

Further commentary on the PACE trial: Biased methods and unreliable outcomes, by
Keith J Geraghty in Journal of Health Psychology [First Published June 14, 2017]

Geraghty in the year 2016, outlines a range of controversies surrounding publication of results from the PACE trial and discusses a freedom of information case brought by a patient refused access to data from the trial. The PACE authors offer a response, writing ‘Dr Geraghty’s views are based on misunderstandings and misrepresentations of the PACE trial’.

This article draws on expert commentaries to further detail the critical methodological failures and biases identified in the PACE trial, which undermine the reliability and credibility of the major findings to emerge from this trial.

Posted in News | Tagged , , , , | Comments Off on Further commentary on the PACE trial: Biased methods & unreliable outcomes

CFS prevalence is grossly overestimated using Oxford criteria compared to CDC (Fukuda) criteria in a US population study

Research abstract:

Chronic fatigue syndrome prevalence is grossly overestimated using Oxford criteria compared to Centers for Disease Control (Fukuda) criteria in a U.S. population study, by James N. Baraniuk in Fatigue: Biomedicine, Health & Behavior [Published online: 21 Jul 2017]

Background:
Results from treatment studies using the low-threshold Oxford criteria for recruitment may have been overgeneralized to patients diagnosed by more stringent chronic fatigue syndrome (CFS) criteria.

Purpose:
To compare the selectivity of Oxford and Fukuda criteria in a U.S. population.

Methods
Fukuda (Center for Disease Control (CDC)) criteria, as operationalized with the CFS Severity Questionnaire (CFSQ), were included in the nationwide rc2004 HealthStyles survey mailed to 6175 participants who were representative of the U.S. 2003 Census population. The 9 questionnaire items (CFS symptoms) were crafted into proxies for Oxford criteria (mild fatigue, minimal exclusions) and Fukuda criteria (fatigue plus ≥4 of 8 ancillary criteria at moderate or severe levels with exclusions). The comparative prevalence estimates of CFS were then determined. Severity scores for fatigue were plotted against the sum of severities for the eight ancillary criteria. The four quadrants of scatter diagrams assessed putative healthy controls, CFS, chronic idiopathic fatigue (CIF), and CFS-like with insufficient fatigue subjects.

Results:
The Oxford criteria designated CFS in 25.5% of 2004 males and 19.9% of 1954 females. Based on quadrant analysis, 85% of Oxford-defined cases were inappropriately classified as CFS. Fukuda criteria identified CFS in 2.3% of males and 1.8% of females.

Discussion
CFS prevalence using Fukuda criteria and quadrant analysis was near the upper limits of previous epidemiology studies. The CFSQ may have utility for on-line and outpatient screening. The Oxford criteria were untenable because they inappropriately selected healthy subjects with mild fatigue and CIF and mislabeled them as CFS.

 

Posted in News | Tagged , , | Comments Off on CFS prevalence is grossly overestimated using Oxford criteria compared to CDC (Fukuda) criteria in a US population study

Neuroendocrine disorder in CFS

Research abstract:

Neuroendocrine disorder in chronic fatigue syndrome, by Slavica TOMIC, Snezana BRKIC, Dajana LENDAK, Daniela MARIC, Milica MEDIC STOJANOSKA, Aleksandra NOVAKOV MIKIC in Turkish Journal of Medical Sciences (2017) 47: sag-1601-110  [Published Online: 17 Dec 2016]

Background/aim:

Neuroendocrine disorders are considered a possible pathogenetic mechanism in chronic fatigue syndrome (CFS). The aim of our study was to determine the function of the hypothalamic–pituitary–adrenal axis (HPA) and thyroid function in women of reproductive age suffering from CFS.

Materials and methods:

The study included 40 women suffering from CFS and 40 healthy women (15–45 years old). Serum levels of cortisol (0800 and 1800 hours), ACTH, total T4, total T3, and TSH were measured in all subjects. The Fibro Fatigue Scale was used for determination of fatigue level.

Results:

Cortisol serum levels were normal in both groups. The distinctively positive moderate correlation of morning and afternoon cortisol levels that was observed in healthy women was absent in the CFS group. This may indicate a disturbed physiological rhythm of cortisol secretion. Although basal serum T4, T3, and TSH levels were normal in all subjects, concentrations of T3 were significantly lower in the CFS group.

Conclusion:

One-time hormone measurement is not sufficient to detect hormonal imbalance in women suffering from CFS. Absence of a correlation between afternoon and morning cortisol level could be a more representative factor for detecting HPA axis disturbance.

Posted in News | Tagged , , , , , | Comments Off on Neuroendocrine disorder in CFS

CBT & objective assessments in CFS

The Journal of Health Psychology has published a short analysis by Graham McPhee on the way that real/objective assessments show that CBT gives no boost to ME/CFS. This is a video to introduce it: Objective Evidence & CFS

Article abstract:

Cognitive behaviour therapy and objective assessments in chronic fatigue syndrome, by Graham McPhee in Journal of Health Psychology [First Published June 19, 2017]

Most evaluations of cognitive behavioural therapy to treat people with chronic fatigue syndrome/myalgic encephalomyelitis rely exclusively on subjective self-report outcomes to evaluate whether treatment is effective. Few studies have used measures appropriate to assessing whether cognitive behavioural therapy changes in more objective measures.

A review of studies incorporating objective measures suggests that there is a lack of evidence that cognitive behavioural therapy produces any improvement in a patient’s physical capabilities or other objective measures such as return to work.

Future studies of chronic fatigue syndrome/myalgic encephalomyelitis should include some objective assessments as primary outcomes. If this is to include activity monitors, we first need a sound baseline dataset.

Posted in News | Tagged , , , | 1 Comment

Countess of Mar asks UK Parliament about NICE & ME/CFS

The Countess of Mar asked written questions to the UK Parliament on the topic of NICE and ME/CFS.

HL637: 10 July 2017

Q.  Her Majesty’s Government who were the experts the National Institute for Health and Clinical Excellence consulted in their recent review of Clinical Guideline CG 53 for chronic fatigue syndrome and myalgic encephalomyelitis: diagnosis and management. [HL637]

A. 19 July 19, 2017
Lord O’Shaughnessy:

The National Institute for Health and Care Excellence (NICE) routinely consults a range of topic experts as part of its surveillance review process. NICE is currently consulting on a review proposal for its clinical guideline on the diagnosis and management of chronic  fatigue syndrome and myalgic encephalomyelitis. NICE does not routinely publish the names of topic experts as they are not part of the decision making process for the surveillance review.

HL684: 11 July 2017

Q. Her Majesty’s Government what assessment they have made of the chronic fatigue syndrome myalgic encephalomyelitis (ME/CFS) clinical services which were set up between 2004 and 2006; what proportion of patients accessing services recover from ME/CFS or show signs of improvement; and what assessment they have made of the value for money of these services.

A. 19 July 2017

Lord O’Shaughnessy:

No central assessment has been made of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) clinical services established between 2004 and 2006. The commissioning of services for people with CFS/ME is a local matter, and the management of patients within such services is the responsibility of the commissioners, providers and clinicians responsible for their care. Clinical commissioning groups have a duty to exercise their functions effectively, efficiently and economically

Since its publication in 2007, the National Institute for Health and Care Excellence (NICE) clinical guideline on the management of CFS/ME in adults and children, which set outs best practice on the care, treatment and support of people with the condition, has supported the local National Health Service in delivering services for people with the condition. The guidance recognises the challenges in managing a condition for which there is no definitive diagnostic test, no clear understanding of the causes and process of disease and no cure. The guidance is also clear that there is no one form of treatment to suit every patient and that treatment and care should take into account the personal needs and preferences of the patient. NICE is currently reviewing the guidance to ensure it reflects the latest available evidence and a decision regarding this matter is expected shortly.

HL685: 11 July 2017

Q.  Her Majesty’s Government whether they have any plans to set up an independent review of ME/CFS services which includes an epidemiological study to establish the true incidence of ME/CFS in the population and the impact of the shortage of doctors trained in this specialism; and, if not, why not.

A. 19 July 2017

Lord O’Shaughnessy:

There are no plans to set up an independent review of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) services. Services for patients with CFS/ME are supported by independent, evidence-based guidance produced by the National Institute for Health and Care Excellence on the diagnosis, treatment and support of patients with the condition. Commissioners should deliver services that meet the needs of local populations.

Assessments of service need for CFS/ME may be supported by the available population prevalence estimates as required.

 

 

 

 

 

Source: UK House of Lords Date: July 19, 2017 URL: http://www.parliament.uk/business/publications/written-questions-answers-statements/written-question/Lords/2017-07-11/HL684/ Ref: http://www.me-net.combidom.com/meweb/web1.4.htm#westminster [Written Answers] [No heading] ———— The Countess of Mar Her Majesty’s Government what assessment they have made of the chronic fatigue syndrome myalgic encephalomyelitis (ME/CFS) clinical services which were set up between 2004 and 2006; what proportion of patients accessing services recover from ME/CFS or show signs of improvement; and what assessment they have made of the value for money of these services. [HL684] Lord O’Shaughnessy No central assessment has been made of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) clinical services established between 2004 and 2006. The commissioning of services for people with CFS/ME is a local matter, and the management of patients within such services is the responsibility of the commissioners, providers and clinicians responsible for their care. Clinical commissioning groups have a duty to exercise their functions effectively, efficiently and economically Since its publication in 2007, the National Institute for Health and Care Excellence (NICE) clinical guideline on the management of CFS/ME in adults and children, which set outs best practice on the care, treatment and support of people with the condition, has supported the local National Health Service in delivering services for people with the condition. The guidance recognises the challenges in managing a condition for which there is no definitive diagnostic test, no clear understanding of the causes and process of disease and no cure. The guidance is also clear that there is no one form of treatment to suit every patient and that treatment and care should take into account the personal needs and preferences of the patient. NICE is currently reviewing the guidance to ensure it reflects the latest available evidence and a decision regarding this matter is expected shortly.

Posted in News | Tagged , , , | Comments Off on Countess of Mar asks UK Parliament about NICE & ME/CFS

The evolution of a ME/CFS researcher? CBT proponent calls for more Herpesvirus research

Simmaron Research blog post, by Cort Johnson, 19 June 2017: The Evolution of a Chronic Fatigue Syndrome (ME/CFS) Researcher? CBT Proponent Calls for More Herpesvirus Research

At times Dr. Wyller of Oslo University has seemed more like a Norwegian version of Simon Wessely than anything else. He’s shown that biological issues were present in ME/CFS, but always manages to come back to the psychological or behavioral elements he believes are perpetuating the disease. His new research, however, is taking him in another direction.

Wyller’s research group has highlighted sympathetic nervous activation and inflammation in chronic fatigue syndrome (ME/CFS) adolescents. His “sustained arousal” hypothesis, however, is a mishmash of physiological (infections, genetics) and psychological components (psychosocial challenges, illness perceptions, poor control over symptoms, “inappropriate learning processes”, personality traits, etc.).

That hypothesis posits that a “false-fatigue alarm” state exists in ME/CFS which is largely held in place by classical and/or operant conditioning. That conditioning can be ameliorated by behavioral techniques which tamp down the “alarm” and the sympathetic nervous system activation.

Wyller’s belief that ME/CFS is an infection/stress triggered disease of sympathetic nervous system (SNS) activation, however, took a hit when clonidine – an SNS inhibitor – actually made ME/CFS adolescents worse. Since SNS activation is arguably present and would certainly contribute to the inflammation in ME/CFS, that result probably shocked just about everyone. It suggested, though, that just as in some cases of POTS, the sympathetic nervous system activation found might be a compensatory, not pathological, response to the illness.

Sustained Arousal’ Hypothesis Not Sustained: Wyller’s Clonidine Trial for Chronic Fatigue Syndrome Fails

Wyller  admits that that CBT’s “effect size” is “modest” and that there is little evidence that it helps sicker patients, but asserts that the evidence-base is “so-solid” that it should be attempted in every patient.

“We believe the evidence base for cognitive behavioural therapy is so solid that all patients with chronic fatigue syndrome/myalgic encephalomyelitis should be offered this treatment.” Wyller et. al.

Wyller 2017: the Evolution of an ME/CFS Researcher?
Wyller may be a CBT/GET apologist, but he’s mostly done physiological research, and whatever his CBT/GET beliefs, it’s difficult to pigeonhole him. His failed Clonidine trial constituted a biological approach to ME/CFS plus his 2016 followup study suggested that a genetic polymorphism in the COMT gene may be responsible for reduced physical activity and impaired sleep and quality of life in some ME/CFS patients.

It’s Wyller’s latest study, however, that takes him into entirely new ground. To his credit, he’s allowing the data to lead him where it will.

Wyller is clearly heavily invested in CBT/GET, while his Norwegian counterparts, Drs. Fluge and Mella, eschew CBT/GET and focus on Rituximab and immune modulation. Wyller mentioned Rituximab in his 2015 overview, but not surprisingly gave it short shrift because of the lack, what else, of follow up studies. But here’s Wyller in 2017 with a study that’s pointing an arrow right at the B-cells in ME/CFS and perhaps even Rituximab.

Whole blood gene expression in adolescent chronic fatigue syndrome: an exploratory cross-sectional study suggesting altered B cell differentiation and survival. Chinh Bkrong Nguyen,1,2 Lene Alsøe,3 Jessica M. Lindvall,4 Dag Sulheim,5 Even Fagermoen,6 Anette Winger,7 Mari Kaarbø,8 Hilde Nilsen,3 and Vegard Bruun Wyller. J Transl Med. 2017; 15: 102. Published online 2017 May 11. doi:  10.1186/s12967-017-1201-0

Using his own definition of ME/CFS, Wyller and his research team took a deep look at gene expression using a technology called high throughput sequencing (HTS) which has not been used before in ME/CFS. You never know what exploratory studies like this will turn up.

The 176 genes whose expression was highlighted in the ME/CFS group most prominently featured a down-regulation of genes involved in B-cell differentiation. The activity of five genes involved in B-cell development, proliferation, migration and survival were significantly reduced in Wyller’s ME/CFS adolescents.

This finding, Wyller reported, jived with findings from the Australians of decreased levels of some B-cells and increased levels of others. (Decreases in the gene expression of genes regulating B-cell proliferation could result in either reductions or increases in different types of B-cells).

At the same time the B-cells in his ME/CFS adolescents were taking a hit, the expression of their innate immune system genes were being upregulated. Interestingly, given the idea that a pathogen is whacking the B-cells in ME/CFS, the expression of several genes associated with pathogen defense were increased in ME/CFS. (Wyller, in fact, reported this was the first time that increased expression of genes associated with innate antiviral responses has been seen in ME/CFS.)

Then, remarkably, Wyller – who recently criticized antivirals as he argued that CBT/GET should be the treatment of choice in ME/CFS – asserted that this finding could reflect problems his ME/CFS adolescents were having with clearing latent herpesviruses.

They “might suggest less efficient viral clearance or reactivation of latent viruses such as members of the herpes virus family, in the CFS group” Study Authors.

Then Wyller suggested that “inefficient viral clearance or reactivation” or chronic viral infection-triggered immune dysfunction warrants further study in ME/CFS.

Then he referred to a remarkable 2014 German study which suggested that a deficient B- and T-cell memory response to EBV may be making it difficult for ME/CFS patients to control EBV infections. That’s really no surprise to the ME/CFS community; it’s long been clear that infectious mononucleosis is a common trigger for people with ME/CFS and FM – but it’s for a CBT proponent to make the connection.

Finally, Wyller’s study suggested that neither inactivity nor mood disorders had any effect on the biological findings presented. (One of his earlier studies discounted the idea that deconditioning was a relevant factor.)

Wyller’s findings are good news, not just because he’s been so committed to his idea that “classical or operant conditioning” perpetuates ME/CFS, or that he’s been such a robust CBT/GET advocate, but because he has shown the ability to get funding.

His next step is to determine how effectively the B cells in ME/CFS are responding to EBV antigens (VCA, EBNA-1) before and after the introduction of stress hormones. If he finds that B-cells are not doing their job with respect to EBV, then both Wyller and the ME/CFS research field are going to have a take a closer look at the role EBV plays in ME/CFS. What a switch that would be!

Wyller isn’t the only one diving back into the herpesviruses.  Two Solve ME/CFS Initiative studies are examining metabolic issues in B-cells and cells infected with HHV-6. Plus studies into B-cell issues in ME/CFS are continuing.

Exhausted Immune System? The SMCI’s Research Program Takes Deep Dive Into Immunity and Energy

One wonders what further positive results would do to Wyller’s view of the appropriate treatments for ME/CFS. Given the tendency of herpes viruses to reactivate during stressful situations, stress reduction techniques (CBT, meditation, MSBR) might, in fact, be useful, but more importantly, so might antivirals, and immune  modulating drugs like Rituximab or cyclophosphamide.

The Biggest Chronic Fatigue Syndrome Treatment Trial Begins: Fluge/Mella On Rituximab

It’s possible that at some point that researchers on both sides of the ME/CFS divide will someday meet in the middle.

Posted in News | Tagged , , , , , | Comments Off on The evolution of a ME/CFS researcher? CBT proponent calls for more Herpesvirus research